Stockscreener 앱 받기
22.31
2.64%
-0.53
전일 마감가:
$22.84
열려 있는:
$22.78
하루 거래량:
170.84K
Relative Volume:
0.07
시가총액:
$2.16B
수익:
$610.16M
순이익/손실:
$-532.93M
주가수익비율:
-4.0353
EPS:
-5.5287
순현금흐름:
$-442.30M
1주 성능:
+2.00%
1개월 성능:
-6.88%
6개월 성능:
-28.80%
1년 성능:
-41.99%
1일 변동 폭
$22.14
$22.84
1주일 범위
$20.61
$23.19
52주 변동 폭
$18.41
$42.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
22.34 | 2.21B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
494.51 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.86 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
733.72 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.35 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.01 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - PR Newswire
Ultragenyx EVP Pinion sells $228k in shares - Investing.com Nigeria
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Financial Times
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire
Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity - GlobeNewswire
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.6%Still a Buy? - MarketBeat
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
FinancialContentUltragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Richtech Robotics Inc. (RR), Ultragenyx Pharmaceutical Inc. (RARE), and Mereo BioPharma Group plc (MREO) Announced by Holzer & Holzer, LLC - marketscreener.com
CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm - Financial Times
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - GlobeNewswire Inc.
Analysis Recap: Can Ultragenyx Pharmaceutical Inc. (UP0) stock stage a strong rebound this quarter2025 Trade Ideas & Community Verified Trade Alerts - Naître et grandir
Ultragenyx Pharmaceutical Inc. $RARE Stock Position Increased by Blue Owl Capital Holdings LP - MarketBeat
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - StreetInsider
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx ... - Bluefield Daily Telegraph
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Ultragenyx Pharmaceutical Inc. (RARE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - FinancialContent
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 – Company Announcement - Financial Times
GW&K Investment Management LLC Buys 668,881 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitRGRD Law - Sahm
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Skeletal Dysplasia Market - GlobeNewswire Inc.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline - NewMediaWire
Robbins LLP Urges RARE Stockholders to Contact the Firm for - GlobeNewswire
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April ... - Bluefield Daily Telegraph
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Rafferty Asset Management LLC - MarketBeat
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Navan, Inc. Notice of April 24, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Insider Sells $228,661.20 in Stock - MarketBeat
Howard Horn Sells 1,635 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $185,478.00 in Stock - MarketBeat
Theodore Alan Huizenga Sells 1,632 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Eric Crombez Sells 7,029 Shares - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells 10,539 Shares - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $190,884.30 in Stock - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) CEO Sells 54,404 Shares - MarketBeat
Ultragenyx (RARE) CEO logs share award and tax-driven stock sale - Stock Titan
Ultragenyx (RARE) legal chief receives stock award, sells shares for taxes - Stock Titan
Ultragenyx (RARE) CAO disposes shares in RSU tax-related transactions - Stock Titan
Ultragenyx (RARE) CFO nets stock award and sells 10,044 shares - Stock Titan
Ultragenyx (RARE) CMO reports stock award and sale of common shares - Stock Titan
Ultragenyx (RARE) executive reports stock grant and tax share surrender - Stock Titan
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.34%
자본화:
|
볼륨(24시간):